JP6999907B2 - 時計遺伝子発現促進用組成物 - Google Patents
時計遺伝子発現促進用組成物 Download PDFInfo
- Publication number
- JP6999907B2 JP6999907B2 JP2019066340A JP2019066340A JP6999907B2 JP 6999907 B2 JP6999907 B2 JP 6999907B2 JP 2019066340 A JP2019066340 A JP 2019066340A JP 2019066340 A JP2019066340 A JP 2019066340A JP 6999907 B2 JP6999907 B2 JP 6999907B2
- Authority
- JP
- Japan
- Prior art keywords
- mass
- composition
- parts
- black ginger
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 94
- 230000014509 gene expression Effects 0.000 title description 50
- 101150038243 CLOCK gene Proteins 0.000 title description 34
- 230000001737 promoting effect Effects 0.000 title description 15
- 241000234314 Zingiber Species 0.000 claims description 63
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 63
- 235000008397 ginger Nutrition 0.000 claims description 63
- 230000027288 circadian rhythm Effects 0.000 claims description 14
- 230000036757 core body temperature Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 229940002508 ginger extract Drugs 0.000 description 34
- 235000020708 ginger extract Nutrition 0.000 description 34
- JRFZSUMZAUHNSL-UHFFFAOYSA-N chrysin 5,7-dimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 JRFZSUMZAUHNSL-UHFFFAOYSA-N 0.000 description 32
- ZXJJBDHPUHUUHD-UHFFFAOYSA-N 4',5,7-Trimethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OC)C=C2O1 ZXJJBDHPUHUUHD-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000000284 extract Substances 0.000 description 23
- ALGDHWVALRSLBT-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one Chemical group C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 ALGDHWVALRSLBT-UHFFFAOYSA-N 0.000 description 22
- 101150074181 PER2 gene Proteins 0.000 description 21
- 230000009471 action Effects 0.000 description 18
- CBTHKWVPSIGKMI-UHFFFAOYSA-N galangin 3,5,7-trimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=CC=C1 CBTHKWVPSIGKMI-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- IAFBOKYTDSDNHV-UHFFFAOYSA-N (2S)-(-)-5,7-dimethoxyflavanone Natural products O1C2=CC(OC)=CC(OC)=C2C(=O)CC1C1=CC=CC=C1 IAFBOKYTDSDNHV-UHFFFAOYSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 101150032765 ARNTL gene Proteins 0.000 description 15
- YZWIIEJLESXODL-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C=C(OC)C=C2O1 YZWIIEJLESXODL-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 101150102464 Cry1 gene Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- KQNCAPDRHYRSCV-UHFFFAOYSA-N 3,5,7-trimethoxyflavone Natural products COC1=C(OC2=CC(=C(C=C2C1=O)OC)OC)C1=CC=CC=C1 KQNCAPDRHYRSCV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- -1 milky Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 241000395050 Kaempferia parviflora Species 0.000 description 3
- 240000000366 Melilotus officinalis Species 0.000 description 3
- 235000017822 Melilotus officinalis Nutrition 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008278 cosmetic cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- 235000008078 Arctium minus Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 description 2
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 240000001085 Trapa natans Species 0.000 description 2
- 235000014364 Trapa natans Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229930182496 polymethoxyflavone Natural products 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 235000009165 saligot Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- YOZUDFLREPPXIO-UHFFFAOYSA-N 3,5,6,7-tetramethoxy-2-phenylchromen-4-one Chemical compound COC=1C(=O)C=2C(OC)=C(OC)C(OC)=CC=2OC=1C1=CC=CC=C1 YOZUDFLREPPXIO-UHFFFAOYSA-N 0.000 description 1
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 241000395033 Kaempferia Species 0.000 description 1
- 235000013422 Kaempferia rotunda Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004585 etidronic acid Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YEHDMSUNJUONMW-UHFFFAOYSA-N methoxyflavone Natural products COC1=CC=CC=C1C1=CC(=O)C2=CC=CC=C2O1 YEHDMSUNJUONMW-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Description
本発明の組成物は、時計遺伝子発現促進作用を奏する有効成分として黒生姜(Kaempferia parviflora)を少なくとも含有する。
全体を100質量部として、黒生姜抽出物 0.01質量部、生姜抽出物 0.01質量部、ケツメイシ 0.01質量部、グリセリン 10質量部、ジグリセリン 3質量部、1,3-ブチレングリコール 12質量部、ペンチレングリコール 3質量部、ヒアルロン酸ナトリウム 0.1質量部、クエン酸 0.01質量部、クエン酸ナトリウム 0.02質量部、キサンタンガム 0.1質量部、メチルパラベン 0.15質量部、カルボマー 0.2質量部、水酸化ナトリウム 0.03質量部及び水 残部を混合して、化粧水の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜抽出物 0.01質量部、ホップ抽出物 0.02質量部、カフェイン 0.01質量部、ラウレス硫酸ナトリウム 7.5質量部、コカミドプロピルベタイン 4.2質量部、コカミドDEA 3質量部、1,3-ブチレングリコール 0.1質量部、ポリクオタニウム-10 0.225質量部、クエン酸 0.15質量部、クエン酸ナトリウム 0.05質量部、フェノキシエタノール 0.9質量部及び水 残部を混合して、シャンプーの態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜粉砕物 0.5質量部、メリロート抽出物 0.2質量部、エラスチン 0.1質量部、グリセリン 2質量部、オリーブ油 1質量部、EDTA-4ナトリウム 0.1質量部、エチドロン酸4ナトリウム 0.2質量部及び石ケン素地 残部を混合及び固化することにより、石鹸の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜抽出物 0.1質量部、アラニン 0.1質量部、アルギニン 0.1質量部、ショ糖脂肪酸エステル 3質量部、グリセリン 12質量部、スクワラン 6質量部、ジメチルシリコーンオイル 24質量部、ポリプロピレングリコール 1質量部、増粘剤 0.06質量部、フェノキシエタノール 0.2質量部、エタノール 5質量部、水酸化ナトリウム 0.01質量部及び精製水 残部を混合して、乳液の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜抽出物 0.1質量部、イソマルトオリゴ糖 0.1質量部、フラクトオリゴ糖 0.1質量部、スクワラン 15.0質量部、ミリスチン酸オクチルドデシル 4.0質量部、水素添加大豆リン脂質 0.2質量部、ブチルアルコール 2.4質量部、硬化油 1.5質量部、ステアリン酸 1.5質量部、親油型モノステアリン酸グリセリン 1.5質量部、モノステアリン酸ポリグリセリル 0.5質量部、ベヘニルアルコール 0.8質量部、モノミリスチン酸ポリグリセリル 0.7質量部、サラシミツロウ 0.3質量部、d-δ-トコフェロール 0.1質量部、メチルパラベン 0.3質量部、C10~30アルキル変性カルボキシビニルポリマー 0.2質量部、カルボキシビニルポリマー 0.1質量部、1,3-ブタンジオール 18.0質量部、水酸化ナトリウム 0.1質量部及び精製水 残部を混合して、化粧クリームの態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜抽出物 0.1質量部、没食子酸 0.01質量部、ポリビニルアルコール 20.0質量部、グリセリン 5.0質量部、エタノール 20.0質量部、カオリン 6.0質量部、防腐剤 0.2質量部、香料 0.1質量部及び精製水 残部を混合して、パック剤の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜粉末 10質量部、ショウガ抽出物 8質量部、カフェイン5質量部、メリロート 5質量部、結晶性セルロース 20質量部、乳糖 50質量部、ステアリン酸マグネシウム 4質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜粉末 10質量部、ケツメイシ末 8質量部、メリロート 5質量部、イソマルトオリゴ糖 0.5質量部、フラクトオリゴ糖 0.5質量部、結晶性セルロース 20質量部、乳糖 50質量部、ステアリン酸マグネシウム 4質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜粉末 10質量部、ホップ末 15質量部、ケツメイシ抽出物 5質量部、乳糖 10質量部、ステアリン酸カルシウム 1質量部及び結晶性セルロース 残部を混合及び顆粒化することにより、顆粒剤の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜抽出物 10質量部、生姜抽出物 20質量部、エラスチン5質量部、レシチン 8質量部及びオリーブ油 残部を混合して調製したものを内容液として、これをカプセル殻に内包することにより、カプセル剤の態様で本発明の組成物を調製した。
全体を100質量部として、黒生姜エキス粉末 0.84質量部、アルギニン 1質量部、アラニン 1質量部、果糖ブドウ糖液糖 10質量部、クエン酸 1質量部、安息香酸ナトリウム 0.02質量部、香料製剤 2質量部、スクラロース 0.05質量部、アセスルファムカリウム 0.03質量部、及び精製水 残部を混合して、液剤の態様で本発明の組成物を調製した。
(1)被験試料群1の調製
黒生姜の乾燥根茎 0.5gを50%エタノール 10mLに加えたものを、30秒のヴォルテックス撹拌処理及び10秒の超音波処理に供し、次いで10分間の振盪処理に供し、次いで遠心分離処理に供した。遠心分離処理により得られた上清を黒生姜50%エタノール抽出物とした。同様に、黒生姜の代わりに黒豆、マッシュルーム、シログワイ、ブロッコリー、サツマイモ、ゴボウ又はトマトを用いた50%エタノール抽出物を調製した。これらの50%エタノール抽出物を被験試料群1とし、後述する遺伝子発現解析に用いた。
黒生姜の乾燥根茎 100gを95%エタノール 1,000mLに加えたものを、6日間の非連続撹拌処理に供し、次いでろ過処理に供した。得られたろ液を蒸発乾燥することにより、黒生姜95%エタノール抽出物(6.8g)を得た。黒生姜95%エタノール抽出物は、後述する分画に用いた。
マウス繊維芽細胞であるNIH-3T3細胞を3日培養したものに、100nM デキサメタゾンを用いて、2時間同調化させた後、被験試料群1を0.5mg/mLとなるようにNIH-3T3細胞に添加した。添加後、所定の時間でNIH-3T3細胞から全RNAを抽出した。時計遺伝子(Per2、Cry1、Bmal1、及びClock)の発現を定量的RT-PCRにより調べた。なお、被験試料群1の代わりに0.5%となるようにエタノールを加えたものをコントロールとした。
黒生姜における時計遺伝子調節機能を有する成分を同定するために、黒生姜95%エタノール抽出物を用いて分取HPLCにより分画を行った。HPLC条件は以下のとおりとした。また、分画した画分のうち、時計遺伝子調節機能を有する成分を含有する画分の同定は、FT-MS及び1H-NMRを用いて行った。
Column:YMC-DispoPack AT ODS-25
Eluent:ACN/H2O(55/45)
Flow Rate:15mL/min
[HPLC条件2]
Column:Wakosil-II5C18 RS-Prep,5μm,20x250mm
Eluent:ACN/MeOH/H2O(20/30/35)
Flow Rate:13mL/min
[HPLC条件3]
Column:Wakosil-II 5C18 RS-Prep,5μm,20x250mm
Eluent:ACN/MeOH/H2O(20/30/30)
Flow Rate:13mL/min
(1)遺伝子発現解析
被験試料群1を添加した6時間後に、時計遺伝子の発現をコントロールに対する相対量として調べた結果を図1に示す。黒生姜を被験試料として用いた場合の4時間毎に経時的に相対的mRNA量を比較した結果を図2に示す。黒生姜の最終濃度を0.005、0.01、0.03及び0.05mg/mLに変化させて、黒生姜を添加した6時間後(Per2及びCry1)又は20時間後(Bmal1)に、時計遺伝子の発現をコントロールに対する相対量として調べた結果を図3に示す。
黒生姜95%エタノール抽出物について、HPLC条件1により分画を実施した。結果を図4に示す。図4に示すとおり、Fr-1~Fr-5までの5つの画分が得られ、これらを乾燥させることにより、それぞれ0.154g、0.537g、0.012g、0.041g及び0.066gの乾燥物を得た。これらの合計回収率は81%であった。
Claims (1)
- 黒生姜を含有する、概日リズム調整用組成物(ただし、深部体温上昇剤を除く)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019066340A JP6999907B2 (ja) | 2019-03-29 | 2019-03-29 | 時計遺伝子発現促進用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019066340A JP6999907B2 (ja) | 2019-03-29 | 2019-03-29 | 時計遺伝子発現促進用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015093534A Division JP6541061B2 (ja) | 2015-04-30 | 2015-04-30 | 時計遺伝子発現促進用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019094357A JP2019094357A (ja) | 2019-06-20 |
JP6999907B2 true JP6999907B2 (ja) | 2022-02-10 |
Family
ID=66972666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019066340A Active JP6999907B2 (ja) | 2019-03-29 | 2019-03-29 | 時計遺伝子発現促進用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6999907B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021131569A1 (ja) * | 2019-12-25 | 2021-07-01 | サントリーホールディングス株式会社 | 睡眠改善用組成物及び概日リズム改善用組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011157302A (ja) | 2010-02-01 | 2011-08-18 | Lion Corp | 深部体温正常化剤および体温正常化組成物 |
JP2013241354A (ja) | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | ホスホジエステラーゼ2阻害剤 |
JP2014015430A (ja) | 2012-07-10 | 2014-01-30 | Toyo Shinyaku Co Ltd | 深部体温上昇剤 |
-
2019
- 2019-03-29 JP JP2019066340A patent/JP6999907B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011157302A (ja) | 2010-02-01 | 2011-08-18 | Lion Corp | 深部体温正常化剤および体温正常化組成物 |
JP2013241354A (ja) | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | ホスホジエステラーゼ2阻害剤 |
JP2014015430A (ja) | 2012-07-10 | 2014-01-30 | Toyo Shinyaku Co Ltd | 深部体温上昇剤 |
Non-Patent Citations (1)
Title |
---|
日本臨床(増刊)最新臨床睡眠学,2013年,71(5),281-286 |
Also Published As
Publication number | Publication date |
---|---|
JP2019094357A (ja) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100323044A1 (en) | Abnormal protein removing method | |
KR101651833B1 (ko) | 감귤류 과피 추출물을 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
JP7643335B2 (ja) | ネムノキ抽出物含有組成物 | |
KR20200063855A (ko) | 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
KR101989407B1 (ko) | 엉겅퀴 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
KR20130077314A (ko) | 피부 개선용 약학 조성물, 화장료 조성물 및 그 제조방법 | |
JP2019163304A (ja) | 黒生姜含有PPARγ発現促進組成物 | |
JP6527715B2 (ja) | 黒生姜含有組成物 | |
JP2011178770A (ja) | 皮膚の色素沈着を抑制する組成物およびその利用 | |
JP6999907B2 (ja) | 時計遺伝子発現促進用組成物 | |
JP6765090B2 (ja) | 黒生姜含有組成物 | |
JP6541061B2 (ja) | 時計遺伝子発現促進用組成物 | |
JP3967238B2 (ja) | 皮膚外用剤 | |
JP4105498B2 (ja) | アトピー性疾患の症状の予防・緩和に有効な組成物 | |
JP6076719B2 (ja) | Cgrp応答性促進剤 | |
JP2004091411A (ja) | 育毛素材及びそれを含有する皮膚外用剤 | |
JP7217550B2 (ja) | 黒生姜含有組成物 | |
JP7617656B2 (ja) | 特定成分含有組成物 | |
KR20240023274A (ko) | 아피게닌-7-오-글루크로나이드를 유효성분으로 포함하는 비만 예방 또는 개선용 조성물 | |
JP5798289B2 (ja) | 異常蛋白質除去用組成物 | |
JP2017088616A (ja) | 黒生姜含有組成物 | |
KR20240023275A (ko) | 2,3,4,5-테트라카페오일글루카릭 엑시드를 유효성분으로 하는 비만 예방 또는 개선용 조성물 | |
JP6151027B2 (ja) | セラミド産生促進剤 | |
CN113892645A (zh) | 用于保护心脏的组合物及其应用 | |
JP2012017270A (ja) | 生体内グリケーション抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210924 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210924 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211022 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211026 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6999907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |